Skip to main content

Market Overview

No­vo Nordisk To Start Phase 3 Obe­si­ty Tri­al With Oral Semaglu­tide

No­vo Nordisk To Start Phase 3 Obe­si­ty Tri­al With Oral Semaglu­tide
  • Novo Nordisk A/S (NYSE: NVOis entering the Phase 3a study in obesity with oral semaglutide 50 mg. The decision follows the completion of the STEP phase 3a trial with once-weekly subcutaneously administered semaglutide 2.4 mg.
  • The company will launch the trial in the second half of 2021, planning to measure a 50 mg semaglutide pill compared to a placebo. The study will recruit about 1,000 patients and last for 68 weeks.
  • “With oral semaglutide, we aim to introduce a convenient and effective treatment option for people with obesity and healthcare providers enabling broader use of anti-obesity medication,” said R&D chief Martin Holst Lange in a statement.
  • Previously, Novo had reported success for semaglutide to treat obesity, which entailed receiving 2.4 mg of the drug through subcutaneous injection once a week. In nearly a 2,000-person trial, patients in the drug arm saw an average of 15% weight loss, compared with just 2.4% on placebo.
  • Price Action: NVO shares are up 1.02% at $74.03 in market hours on the last check Wednesday.

Related Articles (NVO)

View Comments and Join the Discussion!

Posted-In: Briefs obesity Phase 3 TrialBiotech News Health Care General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at